TBRG Investor Alert: Rights for Losses—Act Now!

Company Overview

TruBridge, Inc. (NASDAQ: TBRG) is a healthcare IT and services company specializing in revenue cycle management (RCM) solutions and electronic health records for community hospitals (www.businesswire.com). Formerly part of Computer Programs and Systems, Inc. (CPSI), the company rebranded as “TruBridge” in 2024 to unify its businesses under one brand (www.businesswire.com). TruBridge’s 2024 revenue was $339.2 million with an adjusted EBITDA of $53.1 million (www.businesswire.com), but GAAP earnings were negative due to one-time charges (detailed below). The stock has been volatile – trading from about $17 to $31 in the past year, and currently offers no dividend, reflecting the company’s recent struggles (financhill.com).

Dividend Policy & Yield

TruBridge does not pay any dividend, and none is expected in the foreseeable future (www.sec.gov). The company’s prior quarterly dividend (initiated under CPSI) was indefinitely suspended in September 2020 as the board shifted to conserving cash (www.sec.gov). This suspension coincided with a share repurchase authorization and was partly driven by debt covenant restrictions that limit dividends and buybacks unless certain financial ratios are met (www.sec.gov). With dividends halted, TruBridge’s current dividend yield is 0%, removing any income component for investors (financhill.com). Management has explicitly stated they do not anticipate resuming cash dividends on common stock soon (www.sec.gov), instead prioritizing debt reduction and strategic investments.

Leverage and Debt Maturities

TruBridge carries a significant debt load, largely stemming from credit facilities established when it was part of CPSI. As of year-end 2024, total outstanding borrowings were about $172.8 million, composed of a term loan and revolving credit draw, with maturity in May 2027 (www.sec.gov) (www.sec.gov). Required quarterly principal payments on the term loan are modest (~$0.9 M each), but the bulk of the debt – including any revolver balances – will come due at final maturity (www.sec.gov) (www.sec.gov). The credit agreement is floating-rate: borrowings bear interest at an index (SOFR or base rate) + 1.8% to 3.0% depending on the company’s net leverage ratio (www.sec.gov). In 2024, TruBridge used excess cash to pay down debt, improving its net leverage ratio from ~4× to ~3× EBITDA by year-end (www.businesswire.com). This deleveraging is a positive trend; however, leverage remains elevated relative to cash flow. With ~$165 M coming due in 2027, refinancing or further debt reduction will likely be needed well before maturity. Elevated interest rates also mean interest expense will continue to be a drag on earnings. Investors should monitor TruBridge’s net debt/EBITDA trajectory and plans for addressing the 2027 debt wall.

Interest Coverage and Covenants

TruBridge’s debt covenants have been a pressure point – a red flag for investors. The credit facility requires the company to maintain a fixed charge coverage ratio above a set threshold, as well as keep net leverage below a maximum (www.sec.gov). In late 2023, TruBridge breached its fixed charge coverage covenant (then 1.25× minimum), signaling that earnings were barely sufficient to cover fixed charges like debt service (www.sec.gov). On November 8, 2023, lenders granted a one-time waiver to avoid default, and a subsequent amendment loosened the coverage requirement to 1.15× going forward (www.sec.gov). This covenant relief bought the company time, but underscores tight interest coverage. As of Q4 2024, the company’s trailing coverage was hovering near the minimum – any operational stumble could create covenant issues again. The facility also caps the net leverage ratio at 3.5× EBITDA (with temporary flexibility for acquisitions) (www.sec.gov). TruBridge is now around 3×, safely under the limit, but only after aggressive debt paydown (www.businesswire.com). These covenants effectively prohibit dividends or buybacks unless financial tests are met (www.sec.gov). Investors should be alert: the need for lender waivers in 2023 indicates limited cushion in the financials, and renewed shortfalls in coverage or spikes in leverage (e.g. from an earnings miss or acquisition) could put the company at risk of default on its loans.

Valuation and Performance Metrics

At first glance, TruBridge’s valuation multiples reflect a company with thin profits but decent revenue scale. The stock currently trades around 0.7× annual sales (Price/Sales ≈0.74) and ~1.5× book value (financhill.com), which is modest for a software/tech-enabled services firm. This low P/S ratio likely reflects investors’ concerns about slow growth and margin pressure – total revenue was roughly flat in 2024 and even declined year-over-year in early 2024 due to the divestiture and legacy product weakness (www.businesswire.com). Earnings-based metrics are less meaningful given recent GAAP losses: the trailing P/E is over 90× (or not applicable, since net income was negative) (financhill.com). On a non-GAAP basis (excluding goodwill write-downs and other charges), management reported 2024 adjusted net income of ~$3.5 M (www.businesswire.com) – still a very small profit, implying a rich multiple on “true” earnings. Cash flow and EBITDA provide a better lens: enterprise value (market cap plus net debt) is around 7–8× adjusted EBITDA, which is in line with or slightly below peer averages for healthcare IT services. Compared to pure software peers, TruBridge is cheap on sales multiple, but those peers typically grow faster and have higher margins. Key performance metrics to watch include the RCM segment growth (which was +16% in Q3 2024) versus the declining EHR segment (markets.financialcontent.com), and bookings ($82 M in 2024, roughly matching revenue) as an indicator of future revenue (www.businesswire.com). In sum, the market appears to be pricing in minimal growth and execution risks, but if the company’s turnaround gains traction, there may be upside. Conversely, any further slip in financial performance could leave the stock vulnerable given its small profit base.

Key Risks and Red Flags

TruBridge faces several significant risks and red flags that investors should weigh:

– Stagnant Growth and Industry Challenges: The core target market of small hospitals is saturated and under consolidation pressure (www.sec.gov). TruBridge’s legacy electronic health record (EHR) business (now the “Patient Care” unit) has been shrinking as hospitals merge or upgrade to larger vendors. The company’s ability to offset this with RCM services growth is uncertain, and overall revenue growth is low (2024 guidance had to be revised downward after Q1) (www.businesswire.com). An unfavorable economic or healthcare spending environment could further limit new sales (www.sec.gov).

– Profitability and Cash Flow Risks: TruBridge’s profit margins are slim. It reported a GAAP net loss of $23 M in 2024, due largely to non-cash charges, but even on an adjusted basis profitability is modest (www.businesswire.com). The company took a $35.9 M goodwill impairment in 2024 (plus $2.3 M write-down of a legacy trademark) (www.businesswire.com) – a red flag that past acquisitions (or business units) have declined in value. While these write-offs are non-cash, they indicate management overestimated future earnings from those assets. Ongoing amortization of acquired intangibles will continue to weigh on GAAP earnings. Low earnings also mean interest coverage is precarious, as discussed, leaving little room for error if costs rise or revenue falls.

– High Leverage and Financial Strain: With a debt-to-EBITDA near 3× and $173 M in debt maturing in 2027, TruBridge is leveraged for a company its size (www.sec.gov) (www.sec.gov). Debt servicing consumes a substantial share of cash flow, and rising interest rates increase the burden. As noted, the company came close to breaching debt covenants in 2023 and required a lender waiver (www.sec.gov). Such events highlight financial strain and could recur if performance disappoints. A highly leveraged balance sheet also limits strategic flexibility – management’s options for funding growth or returning capital to shareholders are constrained until debt is reduced.

– Internal Control Weakness and Accounting Issues: Investors should be alarmed that TruBridge’s internal controls over financial reporting have been deficient. The company disclosed a material weakness in its revenue recognition processes, which led to revenue being improperly recognized in 2023 (www.sec.gov). While the misstatement (a ~$3.5 M over-recognition) was not deemed “material” to require a full restatement, it had to be corrected and points to control failures (www.sec.gov). As of year-end 2024, management admitted that this material weakness in revenue accounting was still not fully remediated (www.sec.gov) (www.sec.gov). Although they are working on fixes, a weakness in such a key area raises the risk of future errors or even fraud going undetected (www.sec.gov) (www.sec.gov). Separately, a weakness in review of manual journal entries existed through most of 2024 (though they believe that one was resolved by year-end) (www.sec.gov) (www.sec.gov). These issues undermine confidence in the reliability of reported results and have likely contributed to the stock’s discount.

– Corporate Governance and Shareholder Rights: In March 2024, amid operational and stock price challenges, TruBridge’s board took the unusual step of adopting a shareholder Rights Agreement (poison pill) – issuing one preferred share purchase Right for each common share outstanding (www.sec.gov). This rights plan, triggered if any entity acquires a significant stake, is designed to deter hostile takeovers or activist investors. The move suggests management and the board were concerned about the company’s vulnerability (the stock had fallen ~45% from its 52-week high by that time) and potential outside attempts to seize control. While a rights plan can protect against low-ball bids, it is also a red flag for shareholders: it entrenches the current board/management and limits shareholders’ ability to agitate for change. The adoption of the pill, coupled with risk factor warnings about “activist stockholders” (www.sec.gov), signals a board on the defensive. Investors who have incurred heavy losses may view this as management prioritizing self-preservation over shareholder value, especially since no dividend or buyback is in place to reward long-term holders.

– Competitive and Technological Risk: TruBridge competes against larger, better-capitalized players in both the EHR and RCM arenas (www.sec.gov). Tech giants and specialized firms are investing heavily in modern, cloud-based solutions. TruBridge’s need to modernize its legacy software and transition clients to subscription models is an ongoing challenge (www.sec.gov). Execution missteps – such as delayed product updates, cybersecurity issues, or client dissatisfaction – could erode the customer base. The company has also been offshoring a portion of its services (about 30% of RCM clients to an offshore workforce) to cut costs (www.businesswire.com). This saves money but brings risks related to quality control, data security, and geopolitical exposure. Any major client loss or service failure could have outsized impact given the focused customer niche.

In light of these risks, it’s clear why the stock has struggled. Red flags like covenant breaches, accounting restatements, and poison pills rarely appear in healthy, well-run companies. Investors should remain vigilant and demand improved execution and transparency from management.

Open Questions and Outlook

Looking ahead, several critical questions remain unanswered for TruBridge:

– Can the turnaround deliver sustainable growth? Management touts “transformation” efforts – unified branding, better cost control, offshoring, and focusing on two core business units (www.businesswire.com). However, will these translate into meaningful revenue growth and margin expansion? 2025 guidance only calls for mid-single-digit revenue growth (~$345–$360 M) and a slight EBITDA uptick (www.businesswire.com), suggesting a modest recovery at best. With the EHR/Patient Care segment still in decline, TruBridge essentially relies on RCM services to drive growth. The company’s ability to cross-sell and retain hospital clients in an increasingly competitive RCM market is an open question. Investors will want to see accelerating bookings and revenue – not just cost cuts – to be convinced of a real turnaround.

– Will profitability improve enough to justify investor confidence? Even excluding one-time charges, TruBridge’s net margins are only around 1% of revenue on a non-GAAP basis. The outlook for 2025 (adjusted EBITDA $59–$66 M on ~$350 M sales) implies EBITDA margins of ~17% (www.businesswire.com). After interest, necessary R&D investment, and taxes, true free cash flow may remain modest. Can the company boost margins further (for example, through more automation or offshoring in service delivery)? Or will inflation in labor costs and ongoing software development needs eat up the gains? Until TruBridge demonstrates a clear path to healthier earnings, its valuation may stay depressed – but any upside surprise in profitability could catalyze a re-rating.

– How and when will the debt burden be addressed? With leverage still about 3× EBITDA and major debt maturities looming in 2027 (www.sec.gov) (www.sec.gov), the clock is ticking. Management did well to reduce net debt in 2024, but further significant deleveraging likely requires either asset sales or equity issuance if cash flows stay thin. Another option is refinancing, but that could be costly in a high-interest environment unless the company’s performance and credit metrics improve. This uncertainty over the balance sheet’s future is an overhang. Investors should watch for any strategic moves – such as selling the remaining EHR business or raising equity – that could materially change the leverage profile. The commitment to not pay dividends suggests that for now every spare dollar will go toward debt or reinvestment (www.sec.gov).

– Is management alignment and strategy credible? The adoption of a rights plan raises the question of whether management is truly open to strategic alternatives (including a possible sale or merger). If performance remains sub-par, shareholders may push for changes regardless of the poison pill. An activist investor could still emerge, aiming to force value-unlocking moves (for example, breaking up the company or pursuing a sale). It’s worth questioning management’s long-term plan: Are they positioning TruBridge to be a focused, higher-margin RCM pure-play (having shed the post-acute and perhaps eventually the acute EHR products)? Or is the vision to remain a combined software and services provider despite the challenges? Clarity is needed on how they will compete and grow in the evolving health IT landscape. Additionally, management must follow through on fixing the internal control issues – by the next annual report, investors will expect an unqualified clean bill on controls.

– What will it take to restore shareholder value? TruBridge’s stock is down significantly from its highs, leaving many long-term holders “in the red.” Thus far, management’s steps (cost cuts, rebrand, asset sale of AHT) have stabilized the ship but not materially boosted equity value. Will the company consider reinstating share buybacks once covenants allow, to signal confidence? Or even a small dividend return as debt comes down, to attract income-oriented investors? These actions seem unlikely near-term due to restrictions (www.sec.gov), but investors should watch for any change in tone if financial performance improves. The broader question is whether the current leadership can effectively capitalize on TruBridge’s niche – or whether a larger player might ultimately acquire TruBridge to integrate its RCM capabilities. Ironically, the poison pill suggests the board is resistant to a takeover, yet if the stock languishes, pressure will mount to maximize value one way or another. For now, shareholders have “rights” (literally, per the rights agreement), but realizing value from their losses may require active engagement – be it voicing concerns, pushing for strategic reviews, or organizing with fellow investors. In short, the onus is on management to execute and regain trust; otherwise, outside forces (activists or acquirers) may eventually force the issue.

Bottom Line: TruBridge offers a cautionary tale of a small-cap company encountering multiple hurdles – leverage, integration challenges, control lapses, and strategic crossroads – all reflected in its depressed share price. Investors are on high alert, and time is of the essence for the company to show tangible improvements. Those who have incurred losses should stay informed of their rights and options. Given the mix of risks and potential, shareholders must act diligently now – whether that means re-evaluating the investment case, demanding better accountability from the board, or exploring avenues to recoup losses. The coming quarters will be pivotal in determining if TruBridge’s transformation plan truly rights the ship or if more drastic measures will be needed. 🚩📉

For informational purposes only; not investment advice.